A new autoimmune therapy harnesses a person’s own cells to find and correct other defective cells – an answer for patients who haven’t responded to other treatments and a possible cure for diseases like lupus.
Autoimmune diseases are conditions where the body’s immune system attacks other cells in the body and causes symptoms like inflammation. This happens through autoantibodies, or antibodies that attack the self, produced by a type of white blood known as B cells.
New research tests a type of immunotherapy where T cells, another type of white blood cell, are edited to root out the defective B cells.
The most widely used methods for transdermal administration of the drugs are hypodermic needles, topical creams, and transdermal patches. The effect of most of the therapeutic agents is limited due to the stratum corneum layer of the skin, which serves as a barrier for the molecules and thus only a few molecules are able to reach the site of action. A new form of delivery system called the microneedles helps to enhance the delivery of the drug through this route and overcoming the various problems associated with the conventional formulations. The primary principle involves disruption of the skin layer, thus creating micron size pathways that lead the drug directly to the epidermis or upper dermis region from where the drug can directly go into the systemic circulation without facing the barrier. This review describes the various potential and applications of the microneedles. The various types of microneedles can be fabricated like solid, dissolving, hydrogel, coated and hollow microneedles. Fabrication method selected depends on the type and material of the microneedle. This system has increased its application to many fields like oligonucleotide delivery, vaccine delivery, insulin delivery, and even in cosmetics. In recent years, many microneedle products are coming into the market. Although a lot of research needs to be done to overcome the various challenges before the microneedles can successfully launch into the market.
With billions of dollars flooding into longevity, what role will epigenetic clocks play in measuring and intervening in aging?
When Horvath first described epigenetic clocks, scientists began to speculate that altering them could reverse aging. After all, if certain patterns of DNA methylation at certain sites in cells in certain tissues of your body are hallmarks of aging, could shifting them somehow reverse aging?
The future of mind-controlled machines might not be as far away as we think.
As director of DARPA’s Biological Technologies Office, Dr Justin Sanchez is part of a team that is looking at how to decode brain signals and use them to control robotic prosthetics.
His research includes the visualisation and decoding of brain activity, the development of devices that could help patients with memory deficits, and advanced prosthetic arm systems that could restore feeling and movement after an injury.
The former associate professor of Biomedical Engineering and Neuroscience at the University of Miami has also looked at the potential of neurotechnology for treating paralysis, Tourette’s Syndrome and Obsessive Compulsive Disorder.
In this talk Dr Justin Sanchez takes us through various real world applications of direct neural interfaces.
A research has revealed that taking the over-the-counter painkiller aspirin has potential benefits that outweigh the side effects. Researchers at Cardiff University reviewed the earlier studies of aspirin and cancer and published the findings in the journal Open Biology.
Development of medical treatment against cancer is a major research topic worldwide — but cancer often manages to circumvent the solutions found. Scientists around Tanja Weil and David Ng at the Max Planck Institute for Polymer Research (MPI-P), have now taken a closer look at the cancer’s countermeasures and aim to stop them. By disrupting the cellular components that are responsible for converting oxygen into chemical energy, they have demonstrated initial success in eliminating cells derived from untreatable metastatic cancer.
Treatment of cancer is a long-term process because remnants of living cancer cells often evolve into aggressive forms and become untreatable. Hence, treatment plans often involve multiple drug combinations and/or radiation therapy in order to prevent cancer relapse. To combat the variety of cancer cell types, modern drugs have been developed to target specific biochemical processes that are unique within each cell type.
However, cancer cells are highly adaptive and able to develop mechanisms to avoid the effects of the treatment. “We want to prevent such adaptation by invading the main pillar of cellular life — how cells breathe – that means take up oxygen — and thus produce chemical energy for growth,” says David Ng, group leader at the MPI-P.
The laser that will be the most powerful in the United States is preparing to send its first pulses into an experimental target at the University of Michigan.
Called ZEUS, the Zetawatt-Equivalent Ultrashort pulse laser System, it will explore the physics of the quantum universe as well as outer space, and it is expected to contribute to new technologies in medicine, electronics and national security.
“ZEUS will be the highest peak power laser in the U.S. and among the most powerful laser systems in the world. We’re looking forward to growing the research community and bringing in people with new ideas for experiments and applications,” said Karl Krushelnick, director of the Center for Ultrafast Optical Science, which houses ZEUS, and the Henry J. Gomberg Collegiate Professor of Engineering.
Optimizing Human-System Performance — Dr. Greg Lieberman, Ph.D., Neuroscientist / Lead, U.S. Army Combat Capabilities Development Command Army Research Laboratory, U.S. Army Futures Command
Dr. Greg Lieberman, Ph.D. (https://www.arl.army.mil/arl25/meet-arl.php?gregory_lieberman) is a Neuroscientist, and Lead, Optimizing Human-System Performance, at the U.S. Army Combat Capabilities Development Command, Army Research Laboratory (DEVCOM ARL).
DEVCOM ARL, as an integral part of the Army Futures Command, is the Army’s foundational research laboratory focused on operationalizing science to ensure overmatch in any future conflict. DEVCOM ARL shapes future concepts with scientific research and knowledge and delivers technology for modernization solutions to win in the future operating environment.
With a Ph.D. from the University of Vermont in Neuroscience, a Postdoctoral Fellowship in Cognitive Neuroscience from University of New Mexico, and a BA from University of Massachusetts Amherst in Psychology, Dr. Lieberman’s research and research leadership experience ranges from genetics to learning theory, animal behavior to artificial intelligence, and human variability to team dynamics; with additional expertise in S&T strategy and the opportunities afforded by the Future of Work.
Specific areas of Dr. Lieberman’s technical expertise include maximizing human potential, human-autonomy teaming; neuroanatomical organization and connectivity; brain structure-function coupling; learning-driven neuroplasticity; non-invasive neurostimulation and cognitive enhancement; neuroimaging; mind-body medicine and mindfulness meditation; and the mechanisms of neurodegenerative disease, neuropathology, and brain injury.
